The Trump administration announced on April 22, 2026 that it would move to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. The change would remove the drug’s current status as a Schedule I substance, the same category as heroin, and would open the door for U.S. cannabis companies to access federal banking services and to deduct ordinary operating expenses under Section 280E of the Internal Revenue Code.
Tilray Brands, Inc. stands to benefit directly from the rescheduling. By moving marijuana to Schedule III, Tilray would gain immediate access to federal banking services that have been blocked for Schedule I products, and the company would be able to deduct a broader range of operating costs from its taxable income. The regulatory shift is expected to unlock a medical cannabis market valued at more than $10 billion, providing Tilray with a significant upside to its U.S. growth prospects.
Tilray’s most recent quarterly results, for the period ending August 31, 2025, showed a record net revenue of $210 million, up 5 percent from the $200 million reported in the same quarter a year earlier. The company posted a net income of $1.5 million, a turnaround from a $34.7 million loss in the prior year. The improvement was driven by disciplined cost control, operational efficiency, and a favorable mix of cannabis and distribution revenue, which together offset the impact of a pause in vape sales and international permit delays that had weighed on the previous quarter’s performance.
Irwin D. Simon, Tilray’s Chairman and CEO, said in the earnings release, "As we enter fiscal 2026, Tilray’s first‑quarter results underscore the effectiveness of our strategic vision and disciplined execution. Achieving a record Q1 net revenue of $210 million, delivering net income, and fortifying our balance sheet are not just milestones, they are proof points of our commitment to building sustainable growth, operational excellence, and unlocking value for our shareholders." He added that the company was confident in seizing the transformative opportunities ahead, especially as the U.S. explores cannabis rescheduling and the European cannabis landscape continues to evolve.
Investors reacted positively to the rescheduling announcement, citing the removal of Section 280E tax constraints and the opening of federal banking channels as key drivers. The market view was that these changes would reduce operating costs and improve cash flow, thereby enhancing Tilray’s competitive position in the U.S. market.
The rescheduling process is a formal rule‑making under the Controlled Substances Act and involves scientific and medical evaluations, input from agencies such as HHS and FDA, and a formal rule‑making by the DEA, including a public comment period. While the move to Schedule III does not legalize marijuana nationwide and interstate commerce remains prohibited, it does signal a significant shift in federal policy that could accelerate the growth of the medical cannabis sector.
In summary, the Trump administration’s decision to reclassify marijuana to Schedule III represents a pivotal regulatory development for Tilray and the broader cannabis industry. The change is expected to remove major financial and operational barriers, unlock a sizable medical market, and position Tilray for accelerated growth in the United States.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.